DLL3, an inhibitory notch ligand expressed in most neuroendocrine cancers (NECs), including SCLC, has emerged as a promising target for bsTCE [317] and is undergoing evaluation in a Phase I study for SCLC and NEC (NCT04429087) [321]. Here, DLL3 is linked to neuroendocrine carcinoma.